Source Newsroom: Virginia Commonwealth University
Newswise — Researchers from Virginia Commonwealth University have identified a new anti-tumor gene called SARI that can interact with and suppress a key protein that is overexpressed in 90 percent of human cancers. The discovery could one day lead to an effective gene therapy for cancer.
According to Paul B. Fisher, M.Ph., Ph.D., professor and chair of the Department of Human and Molecular Genetics and director of the VCU Institute of Molecular Medicine in the VCU School of Medicine, and lead investigator of the study, this novel gene highlights a previously unrecognized molecular pathway underlying the anti-tumor action of interferon, INF.
In the study, published online in the Dec. 8 issue of the Proceedings of the National Academy of Sciences, researchers report the discovery of a new gene named SARI, which was uncovered by a powerful technique pioneered in the Fisher laboratory known as subtraction hybridization. SARI, which is induced by a potent immune system modulator called interferon, was found to suppress growth and survival of tumor cells by interfering with the action of cancer cell molecules that drive cell division and promote survival.
The investigators delivered SARI to cancer cells using a virus and the infected cancer cells subsequently stopped dividing and died. Since 90 percent of all cancer types rely on a similar mechanism to proliferate and evade destruction, Fisher noted that SARI could be an effective anti-cancer treatment for many tumors.
"Additionally, IFNs are powerful immune modulating agents that contribute to the immune response to cancer and they are effective inhibitors of new blood vessel formation, the process of angiogenesis, which is obligatory for the growth of both primary and metastatic cancers," said Fisher, who is the first incumbent of the Thelma Newmeyer Corman Endowed Chair in Cancer Research with the VCU Massey Cancer Center.
Currently, IFNs are relevant in the clinical treatment of a number of solid tumors and hematological malignancies, such as melanoma, renal cell carcinoma, malignant glioma, lymphomas and leukemias, either as a monotherapy or as an adjuvant to chemotherapy of radiotherapy.
"We have uncovered a new way by which interferon can induce anti-tumor activity. The identification of SARI also provides a new potential reagent for the selective killing of tumor cells," said Fisher.
"The present study indicates that interferon can suppress cancer growth by inhibiting expression of a cancer-dependent transcription factor that controls genes that regulate cancer cell growth. The SARI gene may provide novel and selective gene therapy applications for cancer. It could also prove amenable for inhibiting proliferative disorders that depend on AP-1 activity," he said. AP-1 plays a key role in regulating proliferation and transformation of cancer cells.
The team is now developing improved approaches to more effectively target the delivery of SARI. Fisher said these studies will be crucial for exploiting the cancer-selective killing activity of this gene and enhancing its therapeutic applications.
This work was supported by grants from the National Institutes of Health, the Samuel Waxman Cancer Research Foundation and the National Foundation for Cancer Research.
Fisher worked with a team that included VCU School of Medicine researchers Zaozhong Su, Ph.D., associate professor in the VCU Department of Human and Molecular Genetics; Devanand Sarkar, Ph.D., assistant professor and Harrison Endowed Scholar in Cancer Research at the VCU Massey Cancer Center, the VCU Institute of Molecular Medicine and the Department of Human and Molecular Genetics; Seok-Geun Lee, Ph.D., assistant professor at the VCU Massey Cancer Center and the Department of Human and Molecular Genetics; and Kristoffer Valerie, Ph.D., professor at the VCU Massey Cancer Center and Department of Radiation Oncology; and Pankaj Gupta, Ph.D., senior research scientist, Immunomedics Inc., in Belleville, N.J.; Luni Emdad, Ph.D., assistant professor, Mount Sinai School of Medicine in New York; Irina V. Lebdeva, Ph.D, senior scientist, Enzo Biochemicals Inc., Farmington New York.
EDITOR'S NOTE: A copy of the study is available for reporters by email request from firstname.lastname@example.org.
About VCU and the VCU Medical Center: Virginia Commonwealth University is the largest university in Virginia and ranks among the top 100 universities in the country in sponsored research. Located on two downtown campuses in Richmond, VCU enrolls 32,000 students in 205 certificate and degree programs in the arts, sciences and humanities. Sixty-five of the programs are unique in Virginia, many of them crossing the disciplines of VCU's 15 schools and one college. MCV Hospitals and the health sciences schools of Virginia Commonwealth University compose the VCU Medical Center, one of the nation's leading academic medical centers. For more, see www.vcu.edu.
About the VCU Massey Cancer Center: The VCU Massey Cancer Center is one of 64 National Cancer Institute-designated institutions that leads and shapes America's cancer research efforts. Working with all kinds of cancers, the Center conducts basic, translational and clinical cancer research, provides state-of-the-art treatments and clinical trials, and promotes cancer prevention and education. Since 1974, Massey has served as an internationally recognized center of excellence. It offers more clinical trials than any other institution in Virginia, serving patients in Richmond and in four satellite locations. Its 1,000 researchers, clinicians and staff members are dedicated to improving the quality of human life by developing and delivering effective means to prevent, control and ultimately to cure cancer. Visit Massey online at www.massey.vcu.edu or call 1-877-4-MASSEY.